Integrating Drug Distribution and Cellular Response to Better Understand Interpatient Heterogeneity
Many small molecule inhibitors fail in clinical trials, and response to these inhibitors varies between patients. A major underlying reason could be the limited drug distribution. More specifically, how the drug has distributed in the tumor and if it has even hit the target is not routinely evaluated. Here, we present an integrative platform where we combine mass spectrometry imaging (MSI), phosphoproteomics and cyclic immunofluorescence (CyCIF) to map drug distribution and measure cellular response to assess heterogeneous response to therapy.